EyePoint Pharmaceuticals, Inc. is a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company has developed 5 FDA-approved sustained-release treatments in ophthalmology. DEXYCU (dexamethasone intraocular suspension) 9% was approved by U.S. Food and Drug Administration (FDA) on February 9, 2018. YUTIQÂŽ (fluocinolone acetonide intravitreal implant) 0.18 mg, was FDA approved on October 12, 2018. ILUVIENÂŽ (fluocinolone acetonide intravitreal implant) 0.19 mg, a micro-insert licensed to Alimera Sciences, is currently sold directly in the U.S. and several EU countries. RetisertÂŽ(ďŹuocinolone acetonide intravitreal implant) 0.59 mg, an implant, is licensed to and sold by Bausch & Lomb. The Companyâs pre-clinical development program is focused on using its core Durasert and Verisome Technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Source
No articles found.
LoveBug Probiotics brings customers an award-winning range of probiotic supplement...
LoveBug Probiotics brings customers an award-wi...
111,Inc., co-founded by Gang Yu and Junling Liu in 2010, is a leading digital and ...
111,Inc., co-founded by Gang Yu and Junling Liu...
Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focu...
Anthera Pharmaceuticals, Inc., a development st...
EyeGate is developing and commercializing products for treating diseases and disor...
EyeGate is developing and commercializing produ...
Innoviva, Inc. (NASDAQ: INVA) is focused on royalty management. Innovivaâs portf...
Innoviva, Inc. (NASDAQ: INVA) is focused on roy...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Join the National Investor Network and get the latest information with your interests in mind.